HomeAethlon Medical Inc.

Aethlon Medical Inc.

Aethlon Medical Announces Collaboration with University of Pittsburgh on NIH Grant for Head and Neck Cancer

The grant, entitled "Depleting exosomes to improve responses to immune therapy in head and neck squamous cell carcinoma" will profile the biomarkers of exosomes in patients with recurrent and metastatic head and neck cancer and will explore the impact of clinical depletion of exosomes using Aethlon's proprietary Hemopurifier device.

Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications

An EFS for a medical device is similar to a phase 1 study for a drug or biologic and as such this trial will enroll a small number of patients with advanced head and neck cancer who cannot be treated with surgery or radiation.

Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement

"The potential synergy of our two companies' platforms should allow penetration into multiple unaddressed markets," said Timothy C. Rodell, M.D., Interim Chief Executive Officer of Aethlon Medical.

Aethlon Medical Announces Collaboration With Prostate On-Site Project

Aethlon Medical Inc. and its diagnostic subsidiary, Exosome Sciences, in collaboration with the Translational Genomics Research Institute (TGen) and the Prostate On-Site Project (POP), announced that Aethlon, TGen and POP will engage with participants for their studies of chronic traumatic encephalopathy (CTE) in living individuals during the 18th annual Jerry Colangelo Sports Legends Golf Classic in Phoenix.